中山便血 鲜红 怎么办(中山做痔疮手术多久恢复) (今日更新中)

WASHINGTON, Jan. 19 (Xinhua) -- New research published this week in Nature Medicine indicates that targeted drugs such as gefitinib might more effectively treat non-small cell lung cancer if they could be combined with agents that block certain microRNAs.The study, led by investigators with the Ohio State University Comprehensive Cancer Center, shows that overexpression of two genes called MET and EGFR causes the deregulation of six microRNAs, and that this deregulation leads to gefitinib resistance.The findings support the development of agents that restore the levels of these microRNAs. It offers a new strategy for treating non-small cell lung cancer, which is responsible for about 85 percent of the 221,000 lung-cancer cases and 157,000 deaths that occur annually in the United States. It also suggests that measuring the expression levels of certain microRNAs -- those controlled by the MET gene -- might predict which lung-cancer cases are likely to be resistant to gefitinib.Epidermal growth factor receptor (EGFR) is frequently overexpressed in non-small cell lung cancer, and this leads to uncontrolled cell proliferation. Gefitinib selectively inhibits EGFR activation and triggers cancer cells to self-destruct by apoptosis. However, non-small cell lung cancer cells inevitably develop resistance to the drug. The study reveals how this resistance occurs."Our findings suggest that gefitinib resistance that is caused by MET overexpression is at least partly due to miRNA deregulation, " says principal investigator Carlo Croce.

WASHINGTON, Nov. 7 (Xinhua) -- U.S. researchers have demonstrated for the first time that the brain is a key player in regulating glucose (sugar) metabolism in humans.The findings, published Monday in the online edition of the Journal of Clinical Investigation, suggest that drugs targeting the brain and central nervous system could be a novel approach to treating diabetes."The brain is the body's only organ that needs a constant supply of glucose to survive, so it makes sense that it would have some say over how much glucose is produced," said study leader Meredith Hawkins, professor of medicine and director of the Global Diabetes Initiative at Yeshiva University, in a statement. "This role for the brain was demonstrated in earlier studies in rodents, but there was considerable controversy over whether the results could be applied to humans. We hope this study helps to settle the matter."In an earlier study in rodents, researchers showed that activation of potassium channels in the brain's hypothalamus sends signals to the liver that dampen its production of glucose. Those findings, published in Nature in 2005, challenged the conventional thinking that blood sugar production by the liver (the body's glucose factory) is regulated only by the pancreas (which makes insulin to metabolize glucose). But carefully performed studies on dogs, conducted at Vanderbilt University, failed to replicate the results, suggesting the Einstein findings in rodents might not be relevant to higher mammals, including humans.The current study, involving people, was aimed at resolving this controversy. Ten nondiabetic subjects were given oral diazoxide, a drug that activates potassium channels in the hypothalamus. (The drug is not used to treat diabetes.) Hormone secretion by the pancreas was controlled to ensure that any change in sugar production would only have occurred through the drug's effect on the brain. After the researchers administered the drug, blood tests revealed that patients' livers were producing significantly less glucose than before.Hawkins and her team then repeated this in rats, again giving diazoxide orally, achieving similar results. They confirmed that sufficient amounts of diazoxide crossed the blood-brain barrier to affect potassium channels in the hypothalamus. Additional experiments confirmed that diazoxide was working through the brain. Specifically, the researchers were able to completely block the effects of diazoxide by infusing a specific potassium channel blocker directly into the brain."This study confirms that the brain plays a significant role in regulating glucose production by the liver," said lead author Preeti Kishore, assistant professor of medicine. "We are now investigating whether this 'brain-to-liver' pathway is impaired in people with diabetes. If so, we may be able to restore normal glucose regulation by targeting potassium channels in the brain."

ACCRA, Dec. 1 (Xinhua) -- The Ghanaian government allayed the fears of many here on Thursday that it would provide funding for the treatment of persons living with HIV/AIDS in the country.Vice President John Dramani Mahama affirmed this when he addressed a ceremony to mark this year's World AIDS Day at Obuasi, near Kumasi, 270 km north of the capital Accra.Mahama said should the Global Fund pull out of supporting the country, the government would partner with development partners to raise the 5.8 million U. S. dollars needed yearly for the treatment of HIV/AIDS patients."Government will work together with the Ghana AIDS Commission (GAC) and donor partners to ensure that people living with HIV/ AIDS have access to antiretroviral drugs."The Presidency is with you, and whatever we will do to win the fight against HIV/AIDS shall be done," Mahama said.Ghana's HIV/AIDS infection rate, according to official figures, has dropped from 3 percent to the current 1.5 percent, albeit with pockets of higher rates of infection among some populations in the country.Mahama called for more innovativeness in mobilizing resources to avoid the danger of retrogression.Director-General of the GAC Angela El-Adas announced that the Ministry of Health had pledged 2.5 million Ghana cedis (1.66 million dollars) out of the 5.8 million dollars needed for next year.Meanwhile, in the capital, the Ghana Network of Persons Living with HIV and AIDS (NAP+ GHANA) joined persons living with HIV (PLHIV) globally on Thursday to commemorate this year's World AIDS Day."We stand united with our fellow PLHIV and the global HIV and AIDS community by fully supporting the vision of 'Getting to Zero', " Charity Owusu Danso, vice president of NAP+ Ghana, said in a message here.Established in 2005, NAP+GHANA is a network of member associations of persons living with HIV/AIDS in Ghana to represent the views, hopes and aspirations of PLHIV across the country."We are extremely worried. Everyday, we receive reports from PLHIV across the country that anti-retroviral drugs are out of stock or that hospitals or clinics won't give HIV treatment to new patients because there aren't even enough drugs for existing patients, " the statement said.

TOKYO, Jan. 24 (Xinhua) -- Japanese Foreign Minister Koichiro Gemba said Tuesday that Japan will seek to take a less inward- looking stance when it comes to diplomacy in the Asia-Pacific region.Specifically he said that Japan will look to enhance diplomatic ties with China based on mutually beneficial goals."With China, this year marks the 40th anniversary of normalizing diplomatic ties. We will aim to deepen the mutually beneficial relationship based on common strategic interests," Gemba said Tuesday in his first foreign policy speech in parliament.He went on to say that Japan plans to proactively make " concrete efforts" to strengthen its ties with China and establish more "open and multilayered networks" in the best interests of both countries.

SAN FRANCISCO, Dec. 9 (Xinhua) -- Hewlett-Packard (HP) on Friday announced that it is keeping the webOS software alive by contributing it to the open source community.The company said it will make the underlying code of webOS available under an open source license and will engage the open source community to help define the charter of the open source project."WebOS is the only platform designed from the ground up to be mobile, cloud-connected and scalable," Meg Whitman, HP's chief executive officer, said in a statement."By contributing this innovation, HP unleashes the creativity of the open source community to advance a new generation of applications and devices," she added.HP said it will remain active in the development and support of webOS, while the source code will be available for use and improvement by anyone choosing to download it, which means other hardware manufacturers can also use the software.With the help of the open source community, HP can save development and other costs and the new announcement is expected to result in more layoffs from its webOS team, some analysts noted.The webOS is a mobile operating system initially developed by Palm which was acquired by HP last April for 1.2 billion U.S. dollars.In February this year, HP released TouchPad, its first tablet computer which runs the webOS operating system. The device didn't sell well, and HP in August decided to completely shut down webOS hardware business, including TouchPad and webOS phones.HP then said that it will continue to explore options to optimize the value of webOS software going forward.By keeping the software open source, users of webOS devices will continue to receive software improvements and updates in the future, HP noted."As webOS gains traction as an open source alternative in the marketplace, you could see webOS on several different types of devices by any number of vendors. We will explore the viability of putting webOS on devices, just as we do for other leading operating systems," the company said in a corporate blog post.

来源：资阳报